Reprint: Good laboratory practice: preventing introduction of bias at the bench by Macleod, Malcolm R. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprint: Good laboratory practice: preventing introduction of
bias at the bench
Citation for published version:
Macleod, MR, Fisher, M, O'Collins, V, Sena, ES, Dirnagl, U, Bath, PMW, Buchan, A, van der Worp, HB,
Traystman, RJ, Minematsu, K, Donnan, GA & Howells, DW 2009, 'Reprint: Good laboratory practice:
preventing introduction of bias at the bench' Journal of Cerebral Blood Flow and Metabolism, vol 29, no. 2,
pp. 221-223. DOI: 10.1038/jcbfm.2008.101
Digital Object Identifier (DOI):
10.1038/jcbfm.2008.101
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of Cerebral Blood Flow and Metabolism
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Reprint: Good laboratory practice: preventing introduction of bias
at the bench
Malcolm R Macleod1, Marc Fisher2, Victoria O’Collins3,4, Emily S Sena1,3,4, Ulrich
Dirnagl5, Philip MW Bath6, Alistair Buchan7, H Bart van der Worp8, Richard J Traystman9,
Kazuo Minematsu10, Geoffrey A Donnan3,4, and David W Howells3,4
1Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK 2Department of
Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA 3National
Stroke Research Institute, Austin Health, University of Melbourne, Victoria, Australia 4Department
of Medicine, Austin Health, University of Melbourne, Melbourne, Victoria, Australia 5Charité
Department for Experimental Neurology, Center for Stroke Research Berlin, Berlin, Germany
6Stroke Trials Unit, University of Nottingham, Nottingham, UK 7Acute Stroke Program, Nuffield
Department of Medicine, John Radcliffe Hospital, Oxford, UK 8Department of Neurology, Rudolf
Magnus Institute of Neuroscience, University Medical Center, Utrecht, The Netherlands 9Anschutz
Medical Campus, University of Colorado Denver, Aurora, Colorado, USA 10Cerebrovascular
Division, Department of Medicine, National Cardiovascular Center, Osaka, Japan
Abstract
As a research community, we have failed to show that drugs, which show substantial efficacy in
animal models of cerebral ischemia, can also improve outcome in human stroke. Accumulating
evidence suggests this may be due, at least in part, to problems in the design, conduct, and reporting
of animal experiments which create a systematic bias resulting in the overstatement of
neuroprotective efficacy. Here, we set out a series of measures to reduce bias in the design, conduct
and reporting of animal experiments modeling human stroke.
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Nearly 10 years after the first Stroke Therapy Academic Industry Roundtable (STAIR)
participants established guidelines intended to support the translation of neuroprotective
efficacy from bench to bedside (Altman et al, 2001), there is still no clinically effective
neuroprotective drug for stroke. One interpretation of this observation is that measures outlined
in STAIR I have failed to deliver the promised improvements in drug development. However,
a dispassionate analysis of data presented over the last 10 years suggests that the ‘STAIR
hypothesis’—that improvements in animal experimental design will lead to improvements in
translational efficiency—has yet to be adequately tested. Adhering to standards of conducting
and reporting of experiments to reduce the confounding effects of bias and ensure adequate
statistical power, as outlined below, will increase the confidence with which we can assess new
data and maximize our chances of developing effective therapies.
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The original STAIR proposal was that by paying due attention to experimental bias, to the
breadth of physiologic variables known to influence stroke outcome in patients, and by testing
therapies in a range of model systems which might more faithfully reproduce the key facets of
stroke pathophysiology, we would be able to translate what appeared to be clear evidence of
neuroprotective efficacy in animals to the more heterogeneous circumstances of human stroke.
Although we believe strongly that failure to adequately consider variables such as age,
comorbidity, physiologic status, and timing of drug administration contribute to the disparity
between the results of animal models and clinical trials, they have been reviewed elsewhere
(Altman et al, 2001; Bath et al, 1998) and are not the subject of this article.
Analyses of data supporting the efficacy of various neuroprotective strategies (Begg et al,
1996; Crossley et al, 2008; Dirnagl, 2006) have revealed that although many researchers adhere
closely to the ethos of these guidelines, as a community we do not. A simple checklist derived
from the STAIR guidelines to provide an overview of the range of data available for 1,026
candidate therapies (Crossley et al, 2008) revealed that only a few came close to meeting the
STAIR guidelines. A higher score against this checklist was accompanied by a marked
reduction in effect size. This later trend could be seen clearly even within the data for individual
drugs (Grotta, 1995). Moreover, studies which reported measures to avoid bias such as random
allocation to treatment group, masked induction of ischemia, or the masked assessment of
outcome (Macleod et al, 2005, 2008), gave a markedly lower estimate of efficacy. Despite this
there has been some evidence of improvement in study quality, and the performance of animal
stroke studies is substantially better than that for most other models of neurologic disease
(Dirnagl, 2006). And yet, the majority of investigators still do not report whether they took
measures to avoid bias.
Systematic reviews and meta-analyses of data from animal stroke studies suggest that these
studies may be substantially distorted by experimental bias. Taken together, publications
supporting the efficacy of NXY-059 include randomized data with allocation concealment and
masked outcome assessment, but most individual publications do not report these measures.
Analyses of those data suggest that at least half of the reported 44% improvement in outcome
could be attributed to experimental bias, specifically a failure to randomize the allocation to
experimental group, a failure to conceal treatment group allocation from the surgeon or a failure
to blind the assessment of outcome (Macleod et al, in press). Similar observations have been
made of the hypothermia literature, where nonrandomized studies and studies without masked
outcome assessment appear to give a relative overstatement of efficacy of 27% and 19%,
respectively (Macleod et al, 2005). Despite the widely recognized importance of these aspects
of study design, analyses conducted by the collaborative approach to meta analysis and review
of animal data from experimental stroke (CAMARADES) group suggest that only 36% of
studies reported random allocation to treatment group, only 11% report allocation concealment,
and only 29% reported the masked assessment of outcome (Dirnagl, 2006).
A related issue is the number of animals used in experiments. The probability of detecting a
difference of a given size between groups is related to the number of animals in each group,
the size of the difference and the variability in the outcome measure used. However, only 3%
of studies identified in systematic reviews reported using a sample size calculation (Dirnagl,
2006). Importantly, if sample size calculations are based on falsely large estimates of effect
size, studies will not be powered to detect real differences between treatment and control
groups. Indeed, post hoc analysis suggests that most experimental stroke studies have only a
one in three chance of detecting a 20% difference in outcome.
These problems are not unique to the preclinical study of stroke. Clinical stroke trials have had
problems with inadequate sample size (O’Collins et al, 2006) and have also failed to report
whether they took measures to avoid bias (Plint et al, 2006). Indeed Cochrane’s observation
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that ‘when humans have to make observations there is always the possibility of bias’ (Sena et
al, 2007) was a lynchpin of the CONSORT (Consolidated Standards of Reporting Trials)
initiative to improve the reporting, design, conduct, analysis, and interpretation of randomized
controlled trials to inform decision making in health care (Sena et al, 2007; STAIR, 1999).
This initiative led to substantial improvements in the reporting and conduct of clinical trials
(van der Worp et al, 2007).
On the basis of the available evidence it would now seem reasonable to suggest that preclinical
testing in animal models of stroke, and indeed other models of disease, should adopt similar
standards to ensure that decision making is based on high quality unbiased data (Dirnagl,
2006; Weaver et al, 2004). Adoption of such standards would have the added benefit of
reducing wasteful usage of financial and animal resources.
In general, studies should only be considered for publication if their ‘Methods’ section includes
a description of how they have addressed the standards below, or if authors make a cogent
argument for why these standards are not relevant to their work. For these components of a
paper, citation of methods described in previous publications is not considered sufficient. These
requirements should not preclude publication of important observational, pilot or hypothesis-
generating data, but the conclusions of such studies should reflect their preliminary nature.
(1) Animals
The precise species, strain, substrain, and source of animals used should be stated. Where
applicable (for instance in studies with genetically modified animals) the generation should
also be given, as well as the details of the wild-type control group (for instance littermate, back
cross, etc.).
(2) Sample size calculation
The manuscript should describe how the size of the experiment was planned. If a sample size
calculation was performed this should be reported in detail, including the expected difference
between groups, the expected variance, the planned analysis method, the desired statistical
power, and the sample size thus calculated. For parametric data, variance should be reported
as 95% confidence limits or standard deviations rather than as the standard error of the mean.
(3) Inclusion and exclusion criteria
Where the severity of ischemia has to reach a certain threshold for inclusion (for instance a
prespecified decrease in perfusion detected with laser–Doppler flowmetry, or the development
of neurologic impairment of a given severity) this should be stated clearly. Usually, these
criteria should be applied before the allocation to experimental groups. If a prespecified lesion
size is required for inclusion this should be detailed, as well as the corresponding exclusion
criteria.
(4) Randomization
The manuscript should describe the method by which animals were allocated to experimental
groups. If this allocation was by randomization, the method of randomization (coin toss,
computer-generated randomization schedules) should be stated. Picking animals ‘at random’
from a cage is unlikely to provide adequate randomization. For comparisons between groups
of genetically modified animals (transgenic, knockout), the method of allocation to for instance
sham operation or focal ischemia should be described.
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(5) Allocation concealment
The method of allocation concealment should be described. Allocation is concealed if the
investigator responsible for the induction, maintenance, and reversal of ischemia and for
decisions regarding the care of (including the early killing of) experimental animals, has no
knowledge of the experimental group to which an animal belongs. Allocation concealment
might be achieved by having the experimental intervention administered by an independent
investigator, or by having an independent investigator prepare drug individually and label it
for each animal according to the randomization schedule as out-lined above. These
considerations also apply to comparisons between groups of genetically modified animals, and
if phenotypic differences (e.g., coat coloring) prevent allocation concealment this should be
stated.
(6) Reporting of animals excluded from analysis
All randomized animals (both overall and by treatment group) should be accounted for in the
data presented. Some animals may, for very good reasons, be excluded from analysis, but the
circumstances under which this exclusion will occur should be determined in advance, and any
exclusion should occur without knowledge of the experimental group to which the animal
belongs. The criteria for exclusion and the number of animals excluded should be reported.
(7) Masked assessment of outcome
The assessment of outcome is masked if the investigator responsible for measuring infarct
volume, for scoring neurobehavioral outcome or for determining any other outcome measures
has no knowledge of the experimental group to which an animal belongs. The method of
blinding the assessment of outcome should be described. Where phenotypic differences prevent
the masked assessment of for instance neurobehavioral outcome, this should be stated.
(8) Reporting potential conflicts of interest and study funding
Any relationship which could be perceived to introduce a potential conflict of interest, or the
absence of such a relationship, should be disclosed in an acknowledgements section, along
with information on study funding and for instance supply of drugs or of equipment.
We consider that these measures are of central importance to Good Laboratory Practice in the
modeling of cerebral ischemia. Many groups already perform experiments to these high
standards, and we hope that they will now report this in full, and that others follow their lead.
Finally, we do not consider these requirements to represent a final or complete list of
appropriate measures necessary to avoid bias. Future additions may be required as further
evidence emerges and the experience of authors and reviewers evolves.
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